Navigation Links
New Study Data Published in British Journal of Urology Demonstrates Cryoablation Effective for Kidney Cancer
Date:10/25/2007

78 Patients Take Part in Five-Year, Retrospective University of Wisconsin

Study

IRVINE, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: ENDO), an innovative medical device company focused on the development of minimally invasive technologies used by urologists and interventional radiologists for tissue and tumor ablation, announced today that a new five-year retrospective study published in the October issue of the British Journal of Urology demonstrates that cryoablation is an effective treatment for patients with small kidney tumors.

A total of 78 patients who had 88 small tumors (mean tumor size was 2.6 cm in diameter) took part in the study led by Stephen Y. Nakada, M.D., of the Division of Urology at the University of Wisconsin, Madison. The cancerous lesions were ablated through either laparoscopic or percutaneous cryoablation in one operative procedure in 95 percent of the cases and, after a mean follow-up of 19 months, the cancer-specific survival rate was 100 percent and recurrence-free survival rate was 98.7 percent.

Dr. Nakada and the researchers noted that the collaboration between urologists and radiologists is optimal for these patients to best target and guide the ablations. He added that cryoablation was most appropriate for kidney tumors 4 cm or less in diameter.

Craig T. Davenport, President, CEO and Chairman of Endocare, said that "Dr. Nakada's five-year experience is providing additional confirmation and results that support the growing body of academic research that cryoablation treatment for kidney tumors is effective. The results from Dr. Nakada and his colleagues at the University of Wisconsin are quite impressive and we are pleased to see these results receiving recognition in journals like the British Journal of Urology."

Cryoablation is a minimally-invasive and non-surgical therapy that uses the Endocare Cryocare Surgical System(R) to precisely target, freeze and destroy cancerous tissue.

About Endocare

Endocare, Inc. -- http://www.endocare.com -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

Statements contained in this release that are not historical facts are forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those discussed in "Risk Factors" in the Company's Forms 10-K, Forms 10-Q, and other filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. The Company undertakes no obligation to revise, or update publicly, any forward-looking statements for any reason.

Investor Contact: Media Contact: For Additional Information:

Matt Clawson Len Hall Craig T. Davenport, CEO

Allen & Caron, Inc. Allen & Caron, Inc. Michael R. Rodriguez, CFO

(949) 474-4300 (949) 474-4300 Endocare, Inc.

matt@allencaron.com len@allencaron.com (949) 450-5400


'/>"/>
SOURCE Endocare, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Rural Canadians travel far for specialists: study
2. A new study surpasses Gene Therapy Hurdle
3. Tomato Sauce reduces Cancer Risk- Study
4. A question on study of Adult Stem Cell
5. Study on obesity and heart failure
6. National Lung Study in the process
7. Marijuana gateway theory strengthened by study of twins
8. Old theory of adaptation confirmed by new study
9. Study casts doubt on keyboard ills
10. Gene study links endometriosis, infertility
11. Study reveals how stress can make you sick
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... Discover the Rocky Mountain region’s longest running and ... companies. Attendees also get to see the most incredible gardens and home improvement ... , at the Colorado Convention Center - 700 14th St. Denver CO, is an ...
(Date:2/8/2016)... Nevada (PRWEB) , ... February 08, 2016 , ... ... RowdMap, Inc., will be speaking on how healthcare companies can use newly released ... manage the health of a population and intervene and capture the value they ...
(Date:2/7/2016)... Clarkston, Metamora, Michigan (PRWEB) , ... February 07, ... ... correct pelvic organ prolapse with the latest techniques and the most minimally invasive ... for pelvic organ prolapse, particularly after menopause. Other risk factors include surgery to ...
(Date:2/6/2016)... ... 06, 2016 , ... FOR INFORMATION: Gayle ... SURGICAL CONFERENCE & EXPO , WHAT:     , This conference is the largest ... nurses in attendance to study the latest evidence-based recommendations and resources for ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research has shown that ... reduce the frequency and level of relapse. , At the 2016 ... Purpose,” will explore the critical tasks of the recovery phase and beyond including ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... and year-end 2015 results after the Nasdaq market closes ... a live conference call and webcast to discuss its ... February 11, 2016 at 4:30 p.m. Eastern Time (1:30 ... http://www.neurocrine.com . --> Participants can access ...
(Date:2/8/2016)... , February 8, 2016 ... market research report "Ablation Technologies Market by Product (Radiofrequency, ... Pain Management, Cosmetic Surgery, Ophthalmology, Gynecology) - Global Forecasts ... global market over the forecast period of 2015 to ... by 2020, at CAGR of 10.5% from 2015 to ...
(Date:2/8/2016)... LEAWOOD, Kan. , Feb. 8, 2016 ... held organization that formerly specialized in the ... facilities, recently announced that it has divided ... Nueterra Capital. While Nueterra Capital will continue ... advisory services, NueHealth will operate a national ...
Breaking Medicine Technology: